Complete Remission of Recalcitrant Viral Warts under Oral Isotretinoin in a Patient with Low-grade B-cell Lymphoma

PURPOSE The CD20 B-lymphocyte surface antigen expressed by B-cell lymphomas is an attractive target for radioimmunotherapy, treatment using radiolabeled antibodies. We conducted a phase I dose-escalation trial to assess the toxicity, tumor targeting, and efficacy of nonmyeloablative doses of an anti-CD20 monoclonal antibody (anti-B1) labeled with iodine-131 (131I) in 34 patients with B-cell lymphoma who had failed chemotherapy. PATIENTS AND METHODS Patients were first given tracelabeled doses of 131I-labeled anti-B1 (15 to 20 mg, 5 mCi) to assess radiolabeled antibody biodistribution, and then a radioimmunotherapeutic dose (15 to 20 mg) labeled with a quantity of 131I that would deliver a specified centigray dose of whole-body radiation predicted by the tracer dose. Whole-body radiation doses were escalated from 25 to 85 cGy in sequential groups of patients in 10-cGy increments. To evaluate if radiolabeled antibody biodistribution could be optimized, initial patients were given one or two additional tracer doses on successive weeks, each dose preceded by an infusion of 135 mg of unlabeled anti-B1 one week and 685 mg the next. The unlabeled antibody dose resulting in the most optimal tracer biodistribution was also given before the radioimmunotherapeutic dose. Later patients were given a single tracer dose and radioimmunotherapeutic dose preceded by infusion of 685 mg of unlabeled anti-B1. RESULTS Treatment was well tolerated. Hematologic toxicity was dose-limiting, and 75 cGy was established as the maximally tolerated whole-body radiation dose. Twenty-eight patients received radioimmunotherapeutic doses of 34 to 161 mCi, resulting in complete remission in 14 patients and a partial response in eight. All 13 patients with low-grade lymphoma responded, and 10 achieved a complete remission. Six of eight patients with transformed lymphoma responded. Thirteen of 19 patients whose disease was resistant to their last course of chemotherapy and all patients with chemotherapy-sensitive disease responded. The median duration of complete remission exceeds 16.5 months. Six patients remain in complete remission 16 to 31 months after treatment. CONCLUSION Nonmyeloablative radioimmunotherapy with 131I-anti-B1 is associated with a high rate of durable remissions in patients with B-cell lymphoma refractory to chemotherapy.

Download Full-text

Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens

European Journal Of Haematology ◽

10.1034/j.1600-0609.2001.00272.x ◽

2001 ◽

Vol 66 (2) ◽

pp. 94-99 ◽

Cited By ~ 12

Author(s):

Agustin Aviles ◽

Sergio Cleto ◽

Judith Huerta-Guzman ◽

Natividad Neri

Keyword(s):

Complete Remission ◽

Maintenance Therapy ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Interferon Alfa ◽

Poor Risk ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Locoregional treatment of low-grade B-cell lymphoma with CD3�CD19 bispecific antibodies and CD28 costimulation: II. Assessment of cellular immune responses

International Journal of Cancer ◽

10.1002/1097-0215(200002)9999:9999<::aid-ijc1069>3.0.co;2-a ◽

2001 ◽

Vol 91 (4) ◽

pp. 516-522 ◽

Cited By ~ 23

Author(s):

Oliver Manzke ◽

Hans Tesch ◽

Johann Lorenzen ◽

Volker Diehl ◽

Heribert Bohlen

Keyword(s):

Immune Responses ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Bispecific Antibodies ◽

Low Grade ◽

Locoregional Treatment ◽

Cellular Immune Responses ◽

Cd28 Costimulation ◽

Cellular Immune

Download Full-text

Molecular analysis of low grade extranodal marginal zone B-cell lymphoma by alumorph genotyping

Gastroenterology ◽

10.1016/s0016-5085(00)81417-1 ◽

2000 ◽

Vol 118 (4) ◽

pp. A1385

Author(s):

Michele De Boni ◽

Francesco Bertoni ◽

Roman Mullenbach ◽

Enrico Roggero ◽

Angelo Bellumat ◽

...

Keyword(s):

B Cell ◽

Molecular Analysis ◽

Marginal Zone ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Low Grade

Download Full-text

Clinicopathological analysis of splenic red pulp low‐grade B‐cell lymphoma

Pathology International ◽

10.1111/pin.12909 ◽

2020 ◽

Vol 70 (5) ◽

pp. 280-286

Author(s):

Takaharu Suzuki ◽

Hiroaki Miyoshi ◽

Joji Shimono ◽

Keisuke Kawamoto ◽

Fumiko Arakawa ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Low Grade ◽

Clinicopathological Analysis ◽

Splenic Red Pulp ◽

Red Pulp

Download Full-text

Treatment with R-bendamustine followed by Y-90 ibritumomab tiuxetan for relapsed/refractory low-grade B-cell lymphoma

Annals of Oncology ◽

10.1093/annonc/mdx697.030 ◽

2017 ◽

Vol 28 ◽

pp. ix81

Author(s):

Koji Nikkuni ◽

Takashi Abe ◽

Kazue Takai

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Low Grade ◽

Ibritumomab Tiuxetan

Download Full-text

Extranodal marginal zone non Hodgkin's lymphoma of the lung: A ten-year experience

Vojnosanitetski pregled ◽

10.2298/vsp1102150m ◽

2011 ◽

Vol 68 (2) ◽

pp. 150-154 ◽

Cited By ~ 1

Author(s):

Violeta Milosevic ◽

Andrija Bogdanovic ◽

Snezana Jankovic ◽

Maja Perunicic-Jovanovic ◽

Biljana Mihaljevic

Keyword(s):

B Cell ◽

Marginal Zone ◽

Cell Lymphoma ◽

Performance Status ◽

Eastern Cooperative Oncology Group ◽

B Cell Lymphoma ◽

Low Grade ◽

Chop Regimen ◽

Female Ratio ◽

Balt Lymphoma

Background/Aim. Bronchus-associated lymphoid tissue (BALT) lymphoma is a rare subtype of low grade marginal zone B cell lymphoma representing 10% of all MALT lymphomas. The purpose of this study was to analyze the outcome of this group of patients comparing prognostic parameters and therapy modalities. Methods. A total of eight patients with BALT lymphoma had diagnosed between January 1998 - April 2008 at the Institute of Hematology, Clinical Center of Serbia, Belgrade, and they were included in this retrospective analysis. Results. Male/female ratio was 2/6, the median age was 64 years (range 37-67 years). Six patients had nonspecific respiratory symptoms and all of them had B symptoms. The patients were seronegative for HIV, HCV and HBsAg. Three patients had Sjogren's syndrome, rheumatoid arthritis and pulmonary tuberculosis, respectively. Seven patients were diagnosed by transbronchial biopsy and an open lung biopsy was done in one patient. Patohistological findings revealed lymphoma of marginal zone B cell lymphoma: CD20+/CD10-/CD5-/CyclinD1- /CD23-/IgM- with Ki-67+<20% of all cells. According to the Ferraro staging system, five patients had localized disease (CS I-IIE) and three had stage IVE; bulky tumor mass had 3 patients. All patients had Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. Five patients received monochemotherapy with chlorambucil and 3 were treated with CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone). A complete response (CR) was achieved in 5 patients and a partial response (PR) in 3 of them, treated with chlorambucil monotherapy and CHOP regimen. All patients were alive during a median follow-up period of 49 months (range 6- 110 months). Three patients relapsed after monochemotherapy into the other extranodal localization. They were treated with CHOP regimen and remained in stable PR. Conclusion. BALT lymphoma tends to be localised disease at the time of diagnosis, responds well to monochemotherapy with chlorambucil and has a favourable prognosis.

Download Full-text